Merck profit rises as new drugs fill void

(Recasts, adds details, product sales)

NEW YORK, April 19 (Reuters) - Merck & Co. (MRK.N) on Thursday said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.

Merck, which on April 12 preannounced the quarterly earnings trends, posted first-quarter net earnings of $1.7 billion, or 78 cents per share, compared with $1.52 billion, or 69 cents per share, a year earlier.

Merck earned 84 cents per share excluding restructuring charges, matching its forecast of last week.

Company sales rose 7 percent to $5.8 billion, fueled by surging revenue from its newer cholesterol fighters Zetia and Vytorin, new vaccines and the new Januvia diabetes treatment, as well as from strong sales growth of asthma drug Singulair and treatments for high blood pressure.

Merck said its migraine drug MK-0974, a so-called calcitonin gene-related peptide (CGRP) antagonist, is now entering Phase III trials. Data from mid-stage trials of the product will be unveiled at a medical meeting in June, the drugmaker said.

Combined sales of Vytorin and Zetia, which are marketed in partnership with Schering-Plough Corp. (SGP.N), grew 47 percent to $1.2 billion. Singulair sales jumped 25 percent to $1 billion, while combined sales of hypertension drugs Cozaar and Hyzaar rose 14 percent to $798 million. Januvia, a pill introduced in October, posted quarterly sales of $87 million.

Total sales of vaccines -- including Gardasil to prevent cervical cancer and Rotateq to protect against rotavirus infections in young children -- more than tripled to $903 million.

((Reporting by Ransdell Pierson and Edward Tobin, editing by Martin Golan; Reuters Messaging: ransdell.pierson.reuters.com@reuters.net; 646-223-6034; ransdell.pierson@reuters.com))

((Multimedia versions of Reuters Top News are now available for: * 3000 Xtra: visit topnews.session.rservices.com * BridgeStation: view story .134 For more information on Top News: topnews.reuters.com)) Keywords: MERCK RESULTS/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nN19363346